VEGFA and glioblastoma: Additionally, the central role of VEGF in the biology of GBMs, as determined by this computational analysis, may in part explain recently published data showing that older GBM patients benefit more from treatment with the VEGF inhibitor, bevacizumab, than do younger patients [36], [64].